GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Appili Therapeutics Inc (OTCPK:APLIF) » Definitions » EBITDA Margin %

Appili Therapeutics (Appili Therapeutics) EBITDA Margin % : 62.08% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Appili Therapeutics EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Appili Therapeutics's EBITDA for the three months ended in Dec. 2023 was $0.22 Mil. Appili Therapeutics's Revenue for the three months ended in Dec. 2023 was $0.36 Mil. Therefore, Appili Therapeutics's EBITDA margin for the quarter that ended in Dec. 2023 was 62.08%.


Appili Therapeutics EBITDA Margin % Historical Data

The historical data trend for Appili Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Appili Therapeutics EBITDA Margin % Chart

Appili Therapeutics Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EBITDA Margin %
Get a 7-Day Free Trial - -2,698.60 - -1,689.90 -2,427.46

Appili Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -659.43 - -149.40 62.08

Competitive Comparison of Appili Therapeutics's EBITDA Margin %

For the Biotechnology subindustry, Appili Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Appili Therapeutics's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Appili Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Appili Therapeutics's EBITDA Margin % falls into.



Appili Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Appili Therapeutics's EBITDA Margin % for the fiscal year that ended in Mar. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Mar. 2023 )/Revenue (A: Mar. 2023 )
=-5.923/0.244
=-2,427.46 %

Appili Therapeutics's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=0.221/0.356
=62.08 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Appili Therapeutics  (OTCPK:APLIF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Appili Therapeutics EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Appili Therapeutics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Appili Therapeutics (Appili Therapeutics) Business Description

Traded in Other Exchanges
Address
1344 Summer Street, Suite 21, Halifax, NS, CAN, B3H 0A8
Appili Therapeutics Inc is a biopharmaceutical company. The company is engaged in novel antibiotic and anti-infective therapies to help patients suffering from serious infections. Its anti-infective portfolio currently includes major programs namely ATI-2307, ATI-1701, ATI-1503, ATI-1501 and Favipiravir.